Crossmark

Direct and indirect effect of the COVID-19 pandemic on patients with cardiomyopathy

Crossref DOI link: https://doi.org/10.1136/openhrt-2021-001918

Published Online: 2022-01-27

Published Print: 2022-01

Update policy: https://doi.org/10.1136/crossmarkpolicy

Authors

Hammersley, Daniel J https://orcid.org/0000-0002-1164-5993
Buchan, Rachel J

Lota, Amrit S

Mach, Lukas

Jones, Richard E

Halliday, Brian P

Tayal, Upasana

Meena, Devendra

Dehghan, Abbas

Tzoulaki, Ioanna

Baksi, A John

Pantazis, Antonis

Roberts, Angharad M

Prasad, Sanjay K

Ware, James S
Clinical Trials ^BETA

Clinical trials referenced in this document:

nct04468256 at ClinicalTrials.gov

Documents that mention this clinical trial

Direct and indirect effect of the COVID-19 pandemic on patients with cardiomyopathy
https://doi.org/10.1136/openhrt-2021-001918
Funding

Funding for this research was provided by:

Medical Research Council (UK), British Heart Foundation (RE/18/4/34215)

Cardiomyopathy UK

Wellcome (107469/Z/15/Z)

Sam’s Rainbow Foundation

National Institute for Health Research

Royal Brompton & Harefield Cardiovascular Biomedical Research Unit
License Information

License valid from 2022-01-26